FDA/Kaiser Study Questions Merck's Vioxx Cardiovascular Safety

Vioxx at doses greater than 25 mg/day is associated with increased risk of acute myocardial infarction and sudden cardiac death, study says. Pfizer's Celebrex had a lower risk of cardiovascular events, the study finds.